These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1865548)

  • 21. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Tebas P
    Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapies for sepsis. Emerging therapies for sepsis and septic shock.
    Abraham E
    West J Med; 1997 Mar; 166(3):195-200. PubMed ID: 9143195
    [No Abstract]   [Full Text] [Related]  

  • 23. Endotoxin immunization.
    Stephens R; Mythen M
    Intensive Care Med; 2000; 26 Suppl 1():S129-36. PubMed ID: 10786970
    [No Abstract]   [Full Text] [Related]  

  • 24. Monoclonal antibodies: technology and application to gram-negative infections.
    Young LS
    Infection; 1984; 12(4):303-8. PubMed ID: 6208152
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
    Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
    Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The HA-1A monoclonal antibody for gram-negative sepsis.
    N Engl J Med; 1991 Jul; 325(4):279-83. PubMed ID: 2057029
    [No Abstract]   [Full Text] [Related]  

  • 28. Gram-negative bacteraemia: new therapeutic possibilities with anti-endotoxin antibodies.
    Gaffin SL
    Haematol Blood Transfus; 1985; 29():107-11. PubMed ID: 3896966
    [No Abstract]   [Full Text] [Related]  

  • 29. The role of monoclonal antibodies in the management of gram-negative sepsis. Experience with the E5 antibody.
    Gorelick KJ; Chmel H
    Infect Dis Clin North Am; 1991 Dec; 5(4):899-913. PubMed ID: 1783775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticore endotoxin F(ab')2 equine immunoglobulin fragments protect against lethal effects of gram-negative bacterial sepsis.
    Dunn DL; Mach PA; Condie RM; Cerra FB
    Surgery; 1984 Aug; 96(2):440-6. PubMed ID: 6379963
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy of gram-negative sepsis in man with anti-endotoxin antibodies: a review.
    Wortel CH; Ziegler EJ; van Deventer SJ
    Prog Clin Biol Res; 1991; 367():161-78. PubMed ID: 1924425
    [No Abstract]   [Full Text] [Related]  

  • 33. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
    Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
    Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Purified monoclonal antibody to endotoxin core fails to protect mice from experimental gram-negative sepsis.
    Silva AT; Appelmelk BJ; Cohen J
    J Infect Dis; 1993 Jul; 168(1):256-7. PubMed ID: 8515127
    [No Abstract]   [Full Text] [Related]  

  • 36. [Monoclonal antibodies in the treatment of sepsis caused by Gram-negative microorganisms].
    Otero AJ; Linares M
    Rev Cubana Med Trop; 1998; 50(1):31-5. PubMed ID: 9842265
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production, characterization and biological effects of monoclonal antibodies to different parts of the gram-negative lipopolysaccharide core region.
    Appelmelk BJ; Verweij-van Vught M; Brade H; Maaskant J; Schouten W; Thijs B; MacLaren D
    Prog Clin Biol Res; 1988; 272():373-82. PubMed ID: 2455918
    [No Abstract]   [Full Text] [Related]  

  • 38. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Monoclonal anti-endotoxin antibodies in the treatment of patients with sepsis due to Gram-negative bacteria].
    Speelman P; van Deventer SJ
    Ned Tijdschr Geneeskd; 1991 May; 135(20):877-8. PubMed ID: 2046787
    [No Abstract]   [Full Text] [Related]  

  • 40. [Establishment of hybridoma lines and protective study of monoclonal antibodies against lipid A of endotoxins].
    Fu W; Xiao G; Yu P
    Zhonghua Yi Xue Za Zhi; 1995 Mar; 75(3):159-60, 190-1. PubMed ID: 7780823
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.